Behavioral reversal of lithium effects by four inositol isomers correlates perfectly with biochemical effects on the PI cycle: Depletion by chronic lithium of brain inositol is specific to hypothalamus, and inositol levels may be abnormal in postmortem brain from bipolar patients

Neuropsychopharmacology

Volumn 19, Issue 3, 1998, Pages 220-232

  Belmaker, Robert H ^a   Agam, Galila ^a   Van Calker, Dietrich ^b   Richards, Mary H ^c   Kofman, Ora ^a  

^a MENTAL HEALTH CENTER   (Israel)

^b UNIVERSITY OF FREIBURG   (Germany)

^c SANOFI   (France)

Author keywords

Bipolar disorder; Epi inositol; Frontal cortex; Hypothalamus; Inositol; Myo inositol

Indexed keywords

INOSITOL; INOSITOL PHOSPHATE; LITHIUM;

AFFECTIVE NEUROSIS; ARTICLE; DRUG EFFECT; FRONTAL CORTEX; HUMAN; HYPOTHALAMUS; ISOMER; MANIC DEPRESSIVE PSYCHOSIS; PATHOGENESIS; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY;

AGED; ANIMALS; ANTIMANIC AGENTS; BEHAVIOR; BEHAVIOR, ANIMAL; BIPOLAR DISORDER; BRAIN CHEMISTRY; FEMALE; HUMANS; HYPOTHALAMUS; INOSITOL; INOSITOL PHOSPHATES; ISOMERISM; LITHIUM; MALE; MIDDLE AGED; RATS;

EID: 0032171218     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(98)00017-7     Document Type: Article

References (62)

1. + concentrations. Psychiat Res. 27:1989;217-224.
2. Agam G., Shapiro J., Bersudsky Y., Kofman O., Belmaker R.H. Effect of high-dose peripheral inositol. Brain inositol levels and prevention of behavioral changes due to inositol depletion Pharmacol Biochem Behav. 49:1994;341-343.
3. Allison J.H., Stewart M.A. Reduced brain inositol in lithium-treated rats. Nature. 233:1971;267-268.
4. Allison J.H., Blisner M.E., Holland W.M., Hipps P.P., Sherman W.B. Increased myo-inositol-1-phosphate in lithium-treated rats. Biochem Biophys Res Comm. 71:1976;664-670.
5. Allison J.H., Boshans R.L., Hallcher L.M., Packman P.M., Sherman W.R. The effects of lithium on myo-inositol levels in layers of frontal cerebral cortex, in cerebellum, and in corpus callosum in rats. J Neurochem. 34:1980;456-458.
6. Barkai I.A., Dunner D.L., Gross H.A., Mayo P., Fieve R.R. Reduced myo-inositol levels in cerebrospinal fluid from patients with affective disorder. Biol Pyschiatr. 13:1978;65-72.
7. + as secondary, selective, consequences of inositol depletion in 1321N1 cells. Biochem J. 297:1994;529-537.
8. + ions. J Neurochem. 65:1995;2279-2289.
9. Benjamins J.A., Agranoff B.W. Distribution and properties of CDP-diglyceride:inositol transferase from brain. J Neurochem. 16:1969;513-527.
10. Bersudsky Y., Shapiro J., Agam G., Kofman O., Belmaker R.H. Behavioral evidence for the existence of two pools of cellular inositol. Euro Neuropsychopharmacol. 4:1994;463-467.
11. Busa W.B., Gimlich R.L. Lithium-induced teratogenesis in frog embryos prevented by a polyphosphoinositide cycle intermediate or a diacylglycerol analog. Dev Biol. 132:1989;315-324.
12. Deicken R.F., Fein G., Weiner M.W. Abnormal frontal lobe phosphorus metabolism in bipolar disorder. Am J Psychiatr. 152:1995;915-918.
13. 3H]inositol radioactivity and mass of second messenger inositol 1,4,5-triphosphate in monkey cerebral cortex slices. J Neurochem. 59:1992;2332-2335.
14. 2+ flux in blowfly salivary glands. Biochem J. 180:1979;661-665.
15. Ghalayini A., Eichberg J. Purification of phosphatidylinositol synthetase from rat brain by CDP-diacylglycerol affinity chromatography and properties of the purified enzyme. J Neurochem. 44:1985;175-182.
16. Godfrey P.P. Potentiation by lithium of CMP-phosphatidate formation in carbachol-stimulated rat cerebral-cortical slices and its reversal by myo-inositol. Biochem J. 258:1989;621-624.
17. 13C NMR spectroscopy of myo-inositol in human brain in vivo. Mag Res Med. 25:1992;204-210.
18. Hallcher L.M., Sherman W.R. The effect of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. J Biol Chem. 255:1980;10896-10901.
19. Hardy J.A., Wester P., Winblad B., Gezelius C., Bring G., Eriksson A. Patients dying after long terminal phase have acidotic brains. Implications for biochemical measurements on autopsy tissue J Neural Transm. 61:1985;253-264.
20. Haussinger D., Laubenberger J., Dahl V., Ernst T., Bayer S., Langer M., Gerok W., Hennig J. Proton magnetic resonance spectroscopy studies on human brain myo-inositol in hypo-osmolarity and hepatic encephalopathy. Gastroenterology. 107:1994;1475-1480.
21. Hirvonen M.R., Savolainen K. Lithium-induced decrease of brain inositol and increase of brain inositol-1-phosphate is transient. Neurochem Res. 16:1991;905-911.
22. Honchar M.P., Olney J.W., Sherman W.R. Systemic cholinergic agents induce seizures and brain damage in lithium-treated rats. Science. 220:1983;323-325.
23. Honchar M.P., Ackerman K.E., Sherman W.R. Chronically administered lithium alters neither myo-inositol monophosphatase activity nor phosphoinositide levels in rat brain. J Neurochem. 53:1989;590-594.
24. 2+. J Biol Chem. 262:1987;15946-15952.
25. Jope R.S., Williams M.B. Lithium and brain signal transduction systems. Biochem Pharmacol. 47:1994;429-441.
26. Kofman O., Klein E., Newman M., Hamburger R., Kimche O., Nir T., Shimon H., Belmaker R.H. Inhibition by antibiotic tetracyclines of rat cortical noradrenergic adenylate cyclase and amphetamine-induced hyperactivity. Pharmacol Biochem Behav. 37:1990;417-424.
27. Kofman O., Belmaker R.H. Biochemical, behavioral, and clinical studies of the role of inositol in lithium treatment and depression. Biol Psychiatr. 34:1993;839-852.
28. Kofman O., Sherman W.R., Katz V., Belmaker R.H. Restoration of brain myo-inositol levels in rats increases latency to lithium-pilocarpine seizures. Psychopharmacology. 110:1993;229-234.
29. Kreis R., Moss B.D. Cerebral metabolic disturbances in patients with subacute and chronic diabetes mellitus. detection with proton MR spectroscopy Radiology. 184:1992;123-130.
30. Levine J., Gonsalves M., Barbam I., Stier S., Elizur A., Kofman O., Belmaker R.H. Inositol 6 gm daily may be effective in depression but not in schizophrenia. Human Psychopharmacol. 8:1993;49-53.
31. Levine J., Barak Y., Gonsalves M., Szor H., Elizur A., Kofman O., Belmaker R.H. A double-blind controlled trial of inositol treatment of depression. Am J Psychiatr. 152:1995;792-794.
32. Lopes J.M., Henry S.A. Interaction of trans and cis regulatory elements in the IN01 promoter of Saccharomyces cerevisaae. Nuc Acids Res. 14:1991;3987-3994.
33. Lowry O.H., Rosenbrough N.D., Farr A.L., Randall R.J. Protein measurement with the folin-phenol reagent. J Biol Chem. 193:1951;265-275.
34. Lubrich B., Patishi Y., Kofman O., Agam G., Berger M., Belmaker R.H., van Calker D. Lithium-induced inositol depletion in rat brain after chronic treatment is restricted to the hypothalamus. Mol Psychiatr. 2:1997;407-412.
35. Mason R., Biello S.M. A neurophysiological study of a lithium-sensitive phosphoinositide system in the hamster suprachiasmatic (Scn) biological clock in vitro. Neurosci Lett. 144:1992;135-138.
36. Miller B.L., Moats R.A., Shonk T., Ernst T., Woolley S., Ross B.D. Alzheimer disease. Depiction of increased cerebral myo-inositol with proton MR spectroscopy Radiology. 187:1993;433-437.
37. Moscovich D., Belmaker R.H., Agam G., Livne A. Inositol-1-phosphatase in RBC of manic-depressive patients before and during treatment with lithium. Biol Psychiat. 27:1990;552-555.
38. Murphy D.L., Belmaker R.H., Carpenter W.T., Wyatt R.J. Monoamine oxidase in chronic schizophrenia. Studies of hormonal and other factors affecting enzyme activity Brit J Psychiat. 130:1977;151-158.
39. Nahorski S.R., Ragan C.I., Challiss R.A. Lithium and the phosphoinositide cycle. An example of uncompetitive inhibition and its pharmacological consequences Trends Pharmacol Sci. 12:1991;297-303.
40. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science. 258:1992;607-614.
41. Palmer A.M., Lowe S.L., Francis P.T., Bowen D.M. Are post-mortem biochemical studies of human brain worthwhile? Biochem Soc Trans. 16:1988;472-475.
42. Patel S., Meldrum B.S., Fine A. Susceptibility to pilocarpine-induced seizures in rats increases with age. Behav Brain Res. 31:1988;165-167.
43. Patishi Y., Belmaker R.H., Agam G. Effect of age, sex, steroids, brain region, and genetic strain on brain inositol monophosphatase activity. Biol Psychiat. 40:1996;656-659. a.
44. Patishi Y., Belmaker R.H., Bersudsky Y., Kofman O. A comparison of the ability of myo-inositol and epi-inositol to attenuate lithium-pilocarpine seizures in rats. Biol Psychiat. 39:1996;829-832. b.
45. Patishi Y., Lubrich B., Berger M., van Calker D., Kofman O., Belmaker R.H. Differential uptake of myo-inositol in vivo into rat brain areas. Eur Neuropsychopharmacol. 6:1996;73-75. c.
46. 2) receptor induced homologous and heterologous desensitization. Brain Res. 631:1993;349-351.
47. Richards M.H., Belmaker R.H. Epi-inositol is biochemically active in reversing lithium effects on cytidine monophosphorylphosphatidate (Cmp-pa). J Neural Transm. 103:1996;1281-1285.
48. Schuller J.H., Hahn A., Troster F., Schutz A., Schweizer E. Coordinate genetic control of yeast fatty acid synthase genes Fas1 and Fas2 by an upstream activation site common to genes involved in membrane lipid biosynthesis. EMBO J. 11:1992;107-114.
49. Sherman W.R., Leavitt A.L., Honchar M.P., Hallcher L.M., Phillips B.E. Evidence that lithium alters phosphoinositide metabolism. Chronic administration elevates primarily D-myo-inositol-1-phosphate in cerebral cortex of the rat J Neurochem. 36:1981;1947-1951.
50. Sherman W.R., Honchar M.P., Munsell L.Y. Detection of receptor-linked phophoinositide metabolism in brian of lithium-treated rats. Bleasdale J.E., Eichborg J., Hauser C. Inositol and Phosphoinositides. Metabolism and Regulation:1985;49-65 Humana Press, Clifton NJ. a.
51. Sherman W.R., Munsell L.Y., Gish B.G., Honchar M.P. Effects of systemically administered lithium on phosphoinositide metabolism in rat brain, kidney and testis. J Neurochem. 44:1985;798-807. b.
52. Sherman W.R., Gish B.G., Honchar M.P., Munsell L.Y. Effects of lithium on phoshoinositide metabolism in vivo. Fed Proc. 45:1986;2639-2646.
53. Sherman W.R. Lithium and the phosphoinositide signalling system. Birch N.J. Lithium and the Cell. Pharmacology and Biochemistry:1991;121-157 Academic Press, London.
54. Shimon H., Agam G., Belmaker R.H., Hyde T., Kleinman J.E. Reduced inositol levels in frontal cortex of post-mortem brain from bipolar patients and suicides. Am J Psychiatry. 154:1997;1148-1150.
55. Spector R., Lorenzo A.V. Myo-inositol transport through the blood-brain barrier. Neurochem Res. 13:1975;785-787.
56. Taussky H., Shorr E., Kurzmann G.A. A microcolorimetric method for the determination of inorganic phosphorus. J Biol Chem. 20:1953;675-681.
57. Thurston J.H., Sherman W.R., Hauhart R.E., Kloepper R.F. Myo-inositol. A newly identified nonnitrogenous osmoregulatory molecule in mammalian brain Pediatr Res. 26:1989;482-485.
58. Tricklebank M.D., Singh L., Oles R.J. Evidence that a proconvulsant action of lithium is mediated by inhibition of myo-inositol phosphatase in mouse brain. Brain Res. 558:1991;145-148.
59. Whitworth P., Kendall D.A. Effects of lithium on inositol phospholipid hydrolysis and inhibition of dopamine D1 receptor-mediated cyclic AMP formation by carbachol in rat brain slices. J Neurochem. 53:1989;536-541.
60. Williams M.B., Jope R.S. Modulation by inositol of cholinergic- and serotonergic-induced seizures in lithium treated rats. Brain Res. 685:1995;169-178.
61. Wood A.J., Goodwin G.M. A review of the biochemical and neuropharmacological actions of lithium. Psychol Med. 17:1987;579-600.
62. Zilberman-Kaufman M., Agam G., Moscowitz L., Livne A.A., Belmaker R.H. Raised monophosphatase activity in schizophrenic patients. Clin Chim Acta. 209:1992;89-93.